Business Wire - October 23, 2002
Bacterial contamination of platelets is the leading cause of morbidity and mortality from a transfusion-transmitted infection. It is estimated that as many as one in 4,000 transfusions lead to a severe septic reaction and as many as one in 12,000 transfusions can lead to death due to bacterial contamination.
"Bacteria are the most common infectious agents transmitted by blood and are a far greater threat to patient health than viruses such as HIV and hepatitis," said Roslyn Yomtovian, M.D., Director, Blood Bank-Transfusion Medicine Service and Associate Professor, Department of Pathology at the University Hospitals of Cleveland. "The Pall BDS gives us a novel approach to address the long-standing problem of bacterial contamination of platelets; a problem that has been eluding us for years."
The launch of the Pall BDS comes at a time when the nation's leading blood safety experts have called for immediate action from the blood banking community to initiate a program to detect the presence of bacteria in platelets. The risk of receiving a bacterially contaminated platelet is 50- to 250-fold higher than the combined risk of transfusion-related infections from HIV, hepatitis B and C, and human T cell leukemia (HTLV I/II) viruses. The bacterial contamination rate is estimated to range from one in 2,000 to one in 3,000 per platelet unit.
Studies conducted with the strains of bacteria reported to cause 98 percent of the fatalities due to bacterial contaminated platelets in the U.S. have shown that the Pall BDS accurately detects both gram- positive and gram-negative bacteria. The Pall BDS accurately detected bacterial contamination of both apheresis (single donor) platelets and random donor platelets, which comprise all platelets transfused in the U.S.
"By combining our filtration expertise and scientific knowledge of blood Pall was able to develop this novel detection system that can be easily incorporated into the blood banking process with minimal cost, time and technician training," said Sam Wortham, President of the Pall Medical Group. "This is certainly good news for patients and their doctors. This new technology better safeguards public health and improves the standard of care for a blood transfusion."
The Pall BDS is the company's first entry into the diagnostic testing market. It uses changes in oxygen concentration as a result of bacterial growth to provide a practical and reliable detection method. Since the vast majority of bacteria that cause clinically significant problems in patients are either aerobes or facultative anaerobes (bacteria that consume oxygen), changes in the level of oxygen in a platelet sample indicate the presence of bacteria. A specially designed filter in the system allows bacteria, if present, to enter the sample while preventing platelets and other cellular components from contaminating the sample. Following incubation of the sample, oxygen levels are easily measured in the analyzer to obtain a result, which appears as a simple "pass" or "fail" reading. This provides the ability to detect and discard contaminated platelets while also eliminating the need for specialized training or capital equipment expenditures.
Platelets are the blood component most vulnerable to bacterial contamination because they must be stored at room temperature, which facilitates bacterial growth. Detection is complicated by the fact that there are numerous strains of bacteria with varying growth rates and time needed for some strains to proliferate to the point where they can be detected. A reliable method must be able to detect the most common and lethal bacteria that contaminate platelets prior to platelet outdating, which is only five days in the U.S. Since platelets are a highly valuable resource, the method must also be able to detect bacteria without false positive results so that viable platelets are not discarded and wasted.
Approximately 2.1 million platelets are transfused each year in the U.S., primarily as a life-saving therapy for people with cancer and leukemia or bleeding problems.
In addition to the launch in the U.S., the Pall BDS is available in Canada and in several countries throughout Europe. Pall Corporation is involved in extensive research and development in many areas of blood safety. It is the worldwide leader for leukocyte (white blood cell) reduction filtration technologies for both red blood cells and platelets, and was just recently granted FDA approval to market the new RC2D Leukocyte Reduction Filter that processes blood faster and with greater plasma recovery.
About Pall Corporation
Pall Corporation is the global leader in the rapidly growing field of filtration, separations and purification. Pall's business is organized around two broad markets: Life Sciences and Industrial. The Company provides leading-edge products to meet the demanding needs of customers in biotechnology, pharmaceuticals, transfusion medicine, semiconductors, municipal drinking water and aerospace. Total revenue for Pall Corporation is $1.3 billion. The Company is headquartered in East Hills, New York, and has operations in more than 30 countries. Further information can be found on its web site (www.pall.com).
-- In addition to Dr. Yomtovian, several of the nation's blood safety opinion leaders and Pall Corp. executives are available for in-person or telephone interviews
-- A complete press kit including photos of the Pall BDS, bacteria that contaminate platelets, and abstracts of studies are available online at http://www.pall.com/pressroom/BDS or by calling Patrice Radowitz at (516) 801-9104.
-- B-roll of the Pall BDS, patient receiving a blood transfusion, physician sound bite, etc., can be accessed by satellite:
Wednesday, October 23 at 1:15 - 1:30 pm EST and at 3:00 - 3:15 pm EST at: Telstar 6 (C-Band), Transponder 9, Dual Audio 6.2/6.8.
Thursday, October 24, 1:45 - 2:00pm EST at: Telstar 6 (C-Band), Transponder 9, Dual Audio 6.2/6.8.
Friday, October 25, 2:00 - 2:15 pm EST at: Telstar 6 (C-Band), Transponder 9, Dual Audio 6.2/6.8.
If technical difficulties are experienced, please call 312-942-1199 ext. 101.
-- Beta copies of b-roll are also available by calling Patrice Radowitz at (516) 801-9104.
CONTACT: Pall Corporation
Media Inquiries:
Patrice Radowitz, 516/801-9104, Pat_Radowitz@pall.com or
Investor Relations Inquiries:
Diane Foster, 516/801-9102, Diane_Foster@pall.com
http://www.pall.com
SOURCE: Pall Corporation
021023
BW021014
Copyright © 2002 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .